In Peer Reviewed Journals
Akl EA,
Briel M, You JJ, Lamontagne F, Gangji A, Cukierman-Yaffe T, Alshurafa M, Sun X,
Nerenberg KA, Johnston BC, Vera C, Mills EJ, Bassler D, Salazar A, Bhatnagar N,
Busse JW, Khalid Z, Walter S, Cook DJ, Schünemann HJ, Altman DG, Guyatt
GH. LOST to follow-up Information in Trials (LOST-IT): a protocol on the
potential impact. Trials 2009; 10: 40.
Altman DG. Prognostic models: a methodological framework and review of
models for breast cancer. Cancer Invest 2009; 27: 235-243.
Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic
research: validating a prognostic model. BMJ 2009; 338: b605.
Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill
R, Juszczak E, Yu LM, Jacoby R for the DART-AD investigators. The
dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a
randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151-157.
Ballard C, Brown R, Fossey J, Douglas S, Bradley P, Hancock J, James IA, Juszczak E, Bentham P, Burns A, Lindesay J, Jacoby R, O'Brien J, Bullock R, Johnson T, Holmes C, Howard R. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatry 2009; 17: 726-733.
Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM; Balliol
Collaboration [includes Altman DG]. Evaluation and stages of
surgical innovations. Lancet 2009; 374: 1089--1096.
Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and
dementia. Cochrane Database Syst Rev 2009; (1): CD003120.
Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine
for Alzheimer's disease. Cochrane Database Syst Rev 2009; (2): CD001191.
Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. (in Chinese) J Chin Integr Med/Zhong Xi Yi Jie He Xue Bao 2009; 7: 491-494.
Boutron I, Ravaud P. Improving the reporting of clinical research. Br J
Surg 2009; 96: 449-450.
Collins GS, Altman DG. An independent external validation and
evaluation of QRISK cardiovascular risk prediction: a prospective open cohort
study. BMJ 2009; 339: b2584.
Eddleston M, Eyer P, Worek F, Juszczak E, Alder N, Mohamed F,
Senarathna L, Hittarage A, Azher S, Jeganathan K, Jayamanne S, von Meyer L,
Dawson AH, Sheriff MH, Buckley NA. Pralidoxime in acute organophosphorus
insecticide poisoning: a randomised controlled trial. PLoS Med 2009; 6:
e1000104.
Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien PA, Reeves BC, Seiler CM;
Balliol Collaboration [includes Altman DG]. Challenges in evaluating surgical
innovation. Lancet 2009; 374: 1097--1104
Hawton K, Bergen H, Simkin S, Brock A, Griffiths C, Romeri E, Smith KL,
Kapur N, Gunnell D. Effect of withdrawal of co-proxamol on prescribing and
deaths from drug poisoning in England and Wales: time series analysis. BMJ
2009; 338: b2270.
Hemingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ 2009; 339: b4184.
Hróbjartsson A, Pildal J, Chan A-W, Haahr MT, Altman DG, Gøtzsche PC.
Reporting on blinding in trial protocols and corresponding publications
was often inadequate but rarely contradictory. J Clin Epidemiol 2009;62:
967-973.
Jensen AM, Ramasamy A.Treating spider phobia using neuro emotional technique (NET): findings from a pilot study. J Altern Complement Med 2009; 15: 1-11.
Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShanepR, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R; DOMINO-AD team. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzhemier's disease - multicentre RCT. Trials 2009; 10:57.
Kelly DF, Moxon ER, Yu LM, Pollard AJ. Anti-polyribosylribitol phosphate
antibody concentrations and avidities in children since the start of
Haemophilus influenzae type b immunization of infants in the United Kingdom.
Clin Vaccine Immunol 2009; 16: 246-252.
Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, Hutton J, Altman DG. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 2009; 4: e7824.
Lee JMS, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I,
Digby JE, Bannister T, Handa A, Wiesmann T, Durrington P, Channon KM, Neubauer
S, Choudhury RP. Effects of high-dose modified-release nicotinic acid on
atherosclerosis and vascular function: A randomized, placebo-controlled,
magnetic resonance imaging study. J Am Coll Cardiol 2009; 54: 1787-1794.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D, and the PRISMA Group. The
PRISMA Statement for reporting systematic reviews and meta-analyses of studies
that evaluate health care interventions: explanation and elaboration. Ann
Intern Med 2009; 151: W64-W94.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D, and the PRISMA Group. The
PRISMA Statement for reporting systematic reviews and meta-analyses of studies
that evaluate health care interventions: explanation and elaboration. BMJ 2009;
339: b2700.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D, and the PRISMA Group. The
PRISMA Statement for reporting systematic reviews and meta-analyses of studies
that evaluate health care interventions: explanation and elaboration. J Clin
Epidemiol 2009; 62: e1-e34.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D, and the PRISMA Group. The
PRISMA Statement for reporting systematic reviews and meta-analyses of studies
that evaluate health care interventions: explanation and elaboration. PLoS Med
2009; 6: e1000100.
MacPherson H, Altman DG. Improving the quality of reporting acupuncture
interventions: describing the collaboration between STRICTA, CONSORT and the
Chinese Cochrane Centre. J Evidence-Based Med 2009; 2: 57-60.
Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of
interest in prognostic modelling studies after multiple imputation: current
practice and guidelines. BMC Med Res Meth 2009; 9: 57.
Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of
registered and published primary outcomes in randomized controlled trials. JAMA
2009; 302: 977-984.
McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC,
Nicholl J; Balliol Collaboration. No surgical innovation without evaluation: the IDEAL
recommendations. Lancet 2009; 374: 1105--1112.
Mills EJ, Chan A, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis,
and presentation of crossover trials. Trials 2009; 10: 27.
Moher D, Liberati A, Tetzlaff JM, Altman DG and the PRISMA Group.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA
Statement. Ann Intern Med 2009; 151: 264-269.
Moher D, Liberati A, Tetzlaff JM, Altman DG and the PRISMA Group.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA
Statement. BMJ 2009; 339: b2535.
Moher D, Liberati A, Tetzlaff JM, Altman DG and the PRISMA Group.
[Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA
Statement (Chinese edition)]. Chin J Integr Med/Zhong Xi Yi Jie He Xue Bao 2009; 7: 889-896.
Moher D, Liberati A, Tetzlaff JM, Altman DG and the PRISMA Group.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA
Statement. J Clin Epidemiol 2009; 62: 1006-1012.
Moher D, Liberati A, Tetzlaff JM, Altman DG and the PRISMA Group.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA
Statement.Open Med 2009; 3: 123-130.
Moher D, Liberati A, Tetzlaff JM, Altman DG and the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement.Phys Ther 2009; 89: 873-880.
Moher D, Liberati A, Tetzlaff JM, Altman DG and the PRISMA Group.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA
Statement. PLoS Med 2009; 6: e1000097.
Molyneux AJ, Kerr RS, Birks J, Ramzi N, Yarnold J, Sneade M, Rischmiller
J for the ISAT collaborators. Risk of recurrent subarachnoid haemorrhage,
death, or dependence and standardised mortality ratios after clipping and
coiling of an intercranial aneurysm in the International Subarachnoid Aneurysm
Trial (ISAT): long-term follow-up. Lancet Neurol 2009; 8: 427-433.
Moons KGM, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic
research: application and impact of prognostic models in clinical practice. BMJ
2009; 338: b606.
Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and
prognostic research: what, why, and how? BMJ 2009; 338: b375.
Neven B, Leroy S, Decaluwe H, Le Deist F, Picard C, Moshous D, Mahlaoui
N, Debre M, Casanova JL, Dal Cortivo L, Madec Y, Hacein-Bey-Abina S, de Saint
Basile G, de Villartay JP, Blanche S, Cavazzana-Calvo M, Fischer A. Long-term
outcome after haematopoietic stem cell transplantation of a single-centre
cohort of 90 patients with severe combined immunodeficiency: Long-term outcome
of HSCT in SCID. Blood 2009; 113: 4114-4124.
Nüesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, Sterchi R, Altman
DG, Jüni P. The importance of allocation concealment and patient blinding
in osteoarthritis trials: a meta-epidemiologic study. Arthritis Rheum
2009; 61: 1633-1641.
Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Schrer M, Altman DG,Jüni P. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ 2009; 339: b3244.
Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Schrer M, Altman DG,Jüni P. Ausschluss von Patienten aus der Analyse: Auswirkungen auf die Ergebnisse randomisierter kontrollierter Studien - Eine meta-epidemiologische Studie. Dtsch Arztebl 2009; 106: A-1893-A-1898.
O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J,
Rosenwald A, Ott G, Rimsza LM, Holte H, Cazier JB, Johnson NA, Campo E, Chan
WC, Gascoyne RD, Young BD, Staudt LM, Lister TA, Fitzgibbon J. Regions of
acquired uniparental disomy at diagnosis of follicular lymphoma are associated
with both overall survival and risk of transformation. Blood 2009; 113:
2298-2301.
Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S,
Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity
and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate
vaccine in infants. Pediatr Infect Dis J 2009; 28: 186-193.
Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the
evolution of evidence from single studies to meta-analysis, and beyond. Br J
Cancer 2009; 100: 1219-1229.
Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic
research: Developing a prognostic model. BMJ 2009; 338: b604.
Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N,
Margison GP, Middleton MR. Predicting the myelotoxicity of chemotherapy: the
use of pretreatment O6-methylguanine-DNA methyltransferase determination in
peripheral blood mononuclear cells. Melanoma Res 2009 Jun 25. [Epub ahead of
print]
Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, Van
Wijgerden J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H. Safety and
immunogenicity of a new TB vaccine, MVA85A, in M. tuberculosis infected
individuals. Am J Respir Crit Care Med 2009; 179: 724-733.
Simera I, Moher D, Hoey J, Schulz KF, Altman DG. The EQUATOR Network and
reporting guidelines: Helping to achieve high standards in reporting health
research studies. Maturitas 2009; 63: 4-6.
Snape MD, Maclennan JM, Lockhart S, English M, Yu LM, Moxon RE, Pollard
AJ. Demonstration of Immunologic Memory Using Serogroup C Meningococcal
Glycoconjugate Vaccine. Pediatr Infect Dis J 2009; 28: 92-97.
Song F, Loke YK, Walsh T, Glenny A-M, Eastwood AJ, Altman DG.
Methodological problems in the use of indirect comparisons for evaluating
healthcare interventions: survey of published systematic reviews. BMJ 2009;
338: b1147.
Sun X, Briel M, Busse JW, Akl EA, You JJ, Mezja F, Bala M, Diaz-Granados N,
Bassler D, Mertz D, Srinathan SK, Vandvik P, Malaga G, Alshurafa M, Dahm P,
Alonso-Coello P, Heels-Ansdell DM, Bhatnagar N, Johnston BC, Wang L, Walter SD,
Altman DG, Guyatt GH. Subgroup Analysis of Trials is Rarely Easy
(SATIRE): a study protocol for a systematic review to characterize the
analysis, reporting and claim of subgroup effects in randomized trials. Trials
2009; 10: 101.
Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG,
Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K. A pragmatic-explanatory
continuum indicator summary (PRECIS): a tool to help trial designers. J Clin
Epidemiol 2009; 62: 464-475.
Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG,
Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K. A pragmatic-explanatory
continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ
2009; 180: E47-57.
Tuveri M, Caocci G, Efficace F, Medas F, Collins GS, Pisu S. Different
perception of surgical risks between physicians and patients undergoing
laparoscopic cholecystectomy. Surg Laparosc Endosc Percutan Tech 2009;19:
305-311.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow C, Pocock
SJ, Poole C, Schlesselman J, Egger M en nombre de la Iniciativa STROBE. Mejorar
la comunicación de estudios observacionales en epidemiología (STROBE):
Explicación y elaboración. (in Spanish) Gaceta Sanitaria 2009; 23: 158.
Walsh APH, Collins GS, Le Du, M, Walsh DJ, Sills ES. Pre-treatment preferences and characteristics among patients seeking in-vitro fertilisation. Reprod Health 2009; 6: 21.
Welton NJ, Ades AE, Carlin JB, Altman DG, Sterne JAC. Models for
potentially biased evidence in meta-analysis using empirically based priors. J
R Statist Soc A 2009; 172: 119-136.
Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Hill
AV, McShane H. Safety and immunogenicity of boosting BCG vaccinated subjects
with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One
2009; 4: e5934.
Wilkinson P, Alder N, Juszczak E, Matthews H, Merritt C, Montgomery H,
Howard R, Macdonald A, Jacoby R. A pilot randomised controlled trial of a brief
cognitive behavioural group intervention to reduce recurrence rates in late
life depression. Int J Geriatr Psychiatry 2009; 24: 68-75.
Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group.
